Top Page
Purple Biotech
(NASDAQ:PPBT)
Purple Biotech (PPBT) vs. SPDR S&P 500 ETF (SPY)
Purple Biotech Business Overview & Revenue Model
Purple Biotech Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 195.80K | 0.00 | 0.00 | 1.00M |
| Gross Profit | -146.25K | -186.00K | -196.00 | -120.00 | -55.00 | 999.94K |
| EBITDA | -3.55M | -7.05M | -19.88M | -21.49M | -17.52M | -28.41M |
| Net Income | -3.26M | -7.24M | -19.88K | -21.67M | -18.38M | -28.00M |
Balance Sheet | ||||||
| Total Assets | 39.06M | 37.04M | 44.30M | 54.62M | 70.20M | 83.80M |
| Cash, Cash Equivalents and Short-Term Investments | 10.45M | 8.52M | 15.41M | 32.11M | 47.20M | 57.80M |
| Total Debt | 256.00K | 183.00K | 351.00K | 515.00K | 749.00K | 895.00K |
| Total Liabilities | 6.25M | 4.13M | 10.01M | 7.52M | 5.09M | 4.05M |
| Stockholders Equity | 32.77M | 32.86M | 34.21M | 46.91M | 64.83M | 79.39M |
Cash Flow | ||||||
| Free Cash Flow | -5.54M | -14.37M | -19.93M | -16.96M | -15.19M | -12.25M |
| Operating Cash Flow | -6.54M | -14.37M | -19.93M | -16.73M | -15.07M | -12.09M |
| Investing Cash Flow | 727.13K | 509.00K | 13.88M | 19.91M | 13.41M | -49.59M |
| Financing Cash Flow | 10.00M | 6.77M | 5.45M | 1.11M | 1.51M | 68.49M |
Purple Biotech Technical Analysis
Purple Biotech Risk Analysis
Purple Biotech Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $6.87M | -1.33 | -145.65% | ― | ― | 68.59% | |
44 Neutral | $18.80M | -0.11 | ― | ― | ― | 52.39% | |
43 Neutral | $6.50M | -0.62 | -10.56% | ― | ― | 88.64% | |
29 Underperform | $3.96M | -0.06 | -168.95% | ― | ― | 90.27% |
Purple Biotech Corporate Events
On January 12, 2026, Purple Biotech released an updated corporate presentation outlining progress on its CAPTN‑3 tri‑specific antibody platform and near‑term milestones for its oncology pipeline. The company highlighted lead candidate IM1240, a capped CD3x5T4xNKG2A antibody for solid tumors that showed a 300‑fold safety margin versus its non‑capped variant in preclinical models and is slated for GLP toxicology completion, IND submission, and Phase 1 initiation in the second half of 2026. The presentation also positioned Phase 2 assets CM24 (pancreatic cancer) and NT219 (head and neck cancer) as partnership opportunities, with interim Phase 2 data for NT219 expected in 2026 and a Phase 2b start for CM24 contingent on partnering, framing 2026 as a catalyst‑rich year that could de‑risk the CAPTN‑3 platform and potentially enhance Purple Biotech’s standing in the competitive immuno‑oncology space.
The most recent analyst rating on (PPBT) stock is a Hold with a $0.66 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On January 7, 2026, Purple Biotech reported that its tri-specific antibody IM1240, from the CAPTN-3 platform, successfully completed a non-human primate toxicology study, showing dosing tolerance up to 300 times higher than a non-capped comparator with markedly reduced immune-related toxicity and minimal cytokine release. The study also demonstrated a favorable pharmacokinetic profile, including increased systemic exposure and prolonged half-life attributed to IM1240’s capping design and albumin moiety, reinforcing the potential for an expanded therapeutic window and supporting its progression toward first-in-human clinical development with further advanced toxicological assessments planned.
The most recent analyst rating on (PPBT) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On December 15, 2025, Purple Biotech Ltd. held an Extraordinary General Meeting of Shareholders at its headquarters in Rehovot, Israel. During the meeting, all proposals outlined in the company’s Proxy Statement were approved by the shareholders, in accordance with Israeli Companies Law and the company’s articles of association. This approval signifies a strategic alignment among stakeholders, potentially impacting the company’s future operations and market positioning.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On December 11, 2025, Purple Biotech reported positive preclinical data from its CAPTN-3 tri-specific antibody platform at the ESMO Immuno-Oncology Congress 2025. The data highlighted significant anti-tumor activity of two antibodies, IM1240 and IM1305, across different tumor antigens, with IM1240 showing effectiveness even in PD1-resistant models. These findings underscore the platform’s potential applicability across a range of solid tumors and support the company’s development roadmap as it prepares for key milestones in 2026.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On November 19, 2025, Purple Biotech Ltd. released an updated corporate presentation highlighting its innovative drug development efforts. The company is uniquely positioned in the oncology field with its CAPTN-3 platform, which combines T-cell and NK cell engagement to enhance cancer treatment efficacy. The presentation underscores the company’s strategic focus on advancing its oncology pipeline, with promising results from Phase 1 and Phase 2 trials, and a cash balance providing financial runway into the first half of 2027.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On November 14, 2025, Purple Biotech announced its third-quarter financial results and business update. The company highlighted the development of its CAPTN-3 platform, including the initiation of a second tri-specific antibody targeting TROP2 and achieving a manufacturing milestone for IM1240. With a cash position of $10.5 million as of September 30, 2025, Purple Biotech anticipates a cash runway into the first half of 2027, supporting significant milestones. The company plans to conduct toxicology studies and initiate a Phase 1 study for IM1240 in 2026. Financially, Purple Biotech reported a decrease in research and development expenses and operating loss compared to the previous year, primarily due to reduced costs associated with the CM24 Phase 2 study.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On October 29, 2025, Purple Biotech announced a significant manufacturing milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform. This achievement validates the scalability of their platform and positions IM1240 competitively for future development, advancing it towards first-in-human clinical trials with an IND submission planned for 2026. The milestone demonstrates Purple Biotech’s capability to produce complex antibodies with high yield and purity, potentially offering a safer therapeutic profile by limiting immune activation to the tumor microenvironment.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On October 28, 2025, Purple Biotech Ltd. announced an upcoming Extraordinary General Meeting of Shareholders scheduled for December 15, 2025. The meeting aims to approve equity-based awards for the CEO and directors. Shareholders and holders of American Depositary Shares are invited to participate and vote on the proposals. The meeting’s outcome could impact the company’s governance and compensation structure, potentially influencing investor confidence and market perception.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
On October 16, 2025, Purple Biotech received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares (ADSs) have been below $1.00 for 30 consecutive trading days. The company has until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for ten consecutive business days. This notification does not immediately affect the company’s Nasdaq listing or the trading of its ADSs, and the company is considering options to address the deficiency, including adjusting the ratio between its ADSs and ordinary shares.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.